The Serum Tissue Factor Level in Lung Cancer Patients as a Prognostic Factor

Sponsor
National Taiwan University Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT00257179
Collaborator
(none)
200
1

Study Details

Study Description

Brief Summary

This study uses serum tissue factor and tissue factor inhibitor and factor VII to monitor the pre-coagulation status in lung cancer patients and to correlate the pre-coagulation status with clinical staging and prognosis.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The staging of lung cancer was according to tumor size, involvement of lymph node and metastatic status. But there is a different prognosis in cancer patients of the same stage. The coagulation status of cancer patients was considered as an important possible prognostic factor. So in this study, we want to evaluate patients' coagulation status and find the relation of coagulation status and cancer status.

    We thus propose a prospective study using coagulation factors in order to search for the relationship between cancer stage and pre-coagulation status in Taiwanese lung cancer patients. We will also evaluate the potential use of tissue factor as a prognosis predictor in lung cancer patients.

    Study Design

    Study Type:
    Observational
    Observational Model:
    Natural History
    Time Perspective:
    Other
    Study Start Date :
    Jun 1, 2005

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      16 Years to 0 Years
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
      • Patients with newly-diagnosed lung cancer

      • Serum from cancer-free healthy volunteers

      Exclusion Criteria:
      • Chronic renal failure or end-stage renal disease [ESRD] (creatinine [Cr] > 2 )

      • Hyperlipidemia on statin therapy

      • Acute myocardial infarction

      • Tapal or Plavix use

      • Active thromboembolic event

      • Severe liver disease (> child B)

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 National Taiwan University Hospital Taipei Taiwan

      Sponsors and Collaborators

      • National Taiwan University Hospital

      Investigators

      • Principal Investigator: Chong-Jen Yu, M.D., Ph.D., National Taiwan University Hospital

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT00257179
      Other Study ID Numbers:
      • 9461700609
      First Posted:
      Nov 22, 2005
      Last Update Posted:
      Mar 14, 2006
      Last Verified:
      Jun 1, 2005
      Keywords provided by , ,
      Additional relevant MeSH terms:

      Study Results

      No Results Posted as of Mar 14, 2006